Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 03:20:00 07/02/26 am AEDT			5-day change	1st Jan Change
295.50 ^DKK	+5.29%		-20.04%	-9.15%

10:39am	FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs -- Update	DJ
10:30am	US signals crackdown on compounded weight-loss drugs; Hims shares tumble	RE

Health Care Up as Wegovy Pill Buoys Novo Nordisk -- Health Care Roundup

Published on 01/17/2026 at 09:15 am AEDT

Dow Jones

NOVO NORDISK A/S

+5.29%

ELI LILLY AND COMPANY

+3.66%

BAYER AG

+2.20%

Health-care companies rose after a strong launch for one potential blockbuster.

The pill formulation of Danish drug maker Novo Nordisk's Wegovy weight-control medication garnered almost as many prescriptions in the first week of its launch as rival Eli Lilly's blockbuster Zepbound injection had done.

The Supreme Court agreed to hear Bayer's challenge to Roundup litigation, giving the chemicals and pharmaceuticals company new hope in its effort to beat back tens of thousands of claims that its flagship weedkiller causes cancer.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-16-26 1714ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
NOVO NORDISK A/S	295.50DKK	+5.29%	-20.04%	208B
ELI LILLY AND COMPANY	1,058.18USD	+3.66%	+2.03%	947B
BAYER AG	45.80EUR	+2.20%	+2.78%	53.15B

Latest news about Novo Nordisk A/S

10:39am	FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs -- Update	DJ
10:30am	US signals crackdown on compounded weight-loss drugs; Hims shares tumble	RE
07/02	FDA to restrict GLP-1 ingredients used in non-approved compounded drugs	RE
07/02	Sector Update: Health Care Stocks Rise Late Afternoon	MT
07/02	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
07/02	Sector Update: Health Care	MT
07/02	Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market	RE
07/02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week	MT
07/02	US FDA Warns of 'Swift Action' Against Copycat Drugs	MT
07/02	Alert on Novo Nordisk initiating Wegovy commercial withdrawn	RE
07/02	Sector Update: Health Care Stocks Advance Premarket Friday	MT
07/02	Sector Update: Health Care	MT
07/02	Top Premarket Decliners	MT
06/02	Svenska Handelsbanken Upgrades Novo Nordisk to Buy, Boosts PT	MT
06/02	US FDA Warns of 'Swift Action' Against Copycat Drugs	MT
06/02	NOVO NORDISK : UBS is Neutral	ZD
06/02	US President Launches TrumpRx.gov to Offer Branded Drugs at Discounted Prices	MT
06/02	European Midday Briefing : Shares Mixed as Tech Jitters Weigh on Sentiment	DJ
06/02	Novo Nordisk shares rebound as FDA targets illegal drug copies	RE
06/02	Europe's STOXX 600 rebounds in broad based gains; Stellantis plunge drags auto stocks	RE
06/02	FDA to Take Action Against Producers of Copycat Drugs	FW
06/02	Handelsbanken Upgrades Novo Nordisk to Buy - New Sector Favorite	FW
06/02	Landesbank Baden-Württemberg Lowers Price Target for Novo Nordisk to 330 Danish Kroner (from 350), Reiterates Hold - BN	FW
06/02	NOVO NORDISK : JP Morgan reiterates its Buy rating	ZD
06/02	Hims & Hers triggers a price war with a low-cost GLP-1 pill, putting Novo and Lilly under pressure

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

27/03 - Annual General Meeting

More about the company